CKD Trials Across the Age Spectrum: Challenges & Opportunities for Drug Development

• Designing the first global chronic kidney disease trial in children using Jardiance
• Evaluating which clinical trial endpoints are clinically meaningful and acceptable to regulatory authorities for pediatric indications and labeling
• Exploring surrogate biomarkers and adaptive endpoints to reliably gauge efficacy and safety when disease progression is slow
• Maximizing real world data, trial design and drug development programs for future therapies in kidney disease

Speakers:

Jennifer McKenzie

Senior Clinical Program Leader in CRM

Boehringer Ingelheim